Celgene closed the most recent trading day at $87.01, moving -0.45% from the previous trading session. This change was narrower than the S&P 500's 0.53% loss on the day. At the same time, the Dow lost 0.36%, and the tech-heavy Nasdaq lost 0.94%.
Heading into today, shares of the biotechnology company had gained 25.32% over the past month, outpacing the Medical sector's loss of 3.96% and the S&P 500's loss of 1.47% in that time.
CELG will be looking to display strength as it nears its next earnings release, which is expected to be January 24, 2019. The company is expected to report EPS of $2.31, up 15.5% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $3.97 billion, up 13.91% from the prior-year quarter.
Any recent changes to analyst estimates for CELG should also be noted by investors. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. CELG is currently a Zacks Rank #3 (Hold).
Looking at its valuation, CELG is holding a Forward P/E ratio of 8.45. For comparison, its industry has an average Forward P/E of 24.99, which means CELG is trading at a discount to the group.
Also, we should mention that CELG has a PEG ratio of 0.42. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Medical - Biomedical and Genetics industry currently had an average PEG ratio of 1.56 as of yesterday's close.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 58, which puts it in the top 23% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
Image: Bigstock
Celgene (CELG) Stock Moves -0.45%: What You Should Know
Celgene closed the most recent trading day at $87.01, moving -0.45% from the previous trading session. This change was narrower than the S&P 500's 0.53% loss on the day. At the same time, the Dow lost 0.36%, and the tech-heavy Nasdaq lost 0.94%.
Heading into today, shares of the biotechnology company had gained 25.32% over the past month, outpacing the Medical sector's loss of 3.96% and the S&P 500's loss of 1.47% in that time.
CELG will be looking to display strength as it nears its next earnings release, which is expected to be January 24, 2019. The company is expected to report EPS of $2.31, up 15.5% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $3.97 billion, up 13.91% from the prior-year quarter.
Any recent changes to analyst estimates for CELG should also be noted by investors. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. CELG is currently a Zacks Rank #3 (Hold).
Looking at its valuation, CELG is holding a Forward P/E ratio of 8.45. For comparison, its industry has an average Forward P/E of 24.99, which means CELG is trading at a discount to the group.
Also, we should mention that CELG has a PEG ratio of 0.42. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Medical - Biomedical and Genetics industry currently had an average PEG ratio of 1.56 as of yesterday's close.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 58, which puts it in the top 23% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.